CH660964A5 - Arzneimittelpraeparat mit antikarzinogener wirkung. - Google Patents
Arzneimittelpraeparat mit antikarzinogener wirkung. Download PDFInfo
- Publication number
- CH660964A5 CH660964A5 CH90284A CH90284A CH660964A5 CH 660964 A5 CH660964 A5 CH 660964A5 CH 90284 A CH90284 A CH 90284A CH 90284 A CH90284 A CH 90284A CH 660964 A5 CH660964 A5 CH 660964A5
- Authority
- CH
- Switzerland
- Prior art keywords
- effect
- preparation according
- cells
- cancer
- carcinogenic
- Prior art date
Links
- 230000000694 effects Effects 0.000 title claims description 11
- 229940126601 medicinal product Drugs 0.000 title claims description 3
- 238000002360 preparation method Methods 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 14
- 230000003217 anti-cancerogenic effect Effects 0.000 claims description 12
- 210000004881 tumor cell Anatomy 0.000 claims description 12
- -1 polyhexamethylene guanidine phosphate Polymers 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 230000010534 mechanism of action Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229920002873 Polyethylenimine Polymers 0.000 claims 1
- 108010039918 Polylysine Proteins 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000138 intercalating agent Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920000333 poly(propyleneimine) Polymers 0.000 claims 1
- 229920000656 polylysine Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000001792 Sarcoma 37 Diseases 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 208000009956 adenocarcinoma Diseases 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000000711 cancerogenic effect Effects 0.000 description 3
- 231100000315 carcinogenic Toxicity 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/SU1982/000020 WO1984000105A1 (fr) | 1982-06-21 | 1982-06-21 | Preparation medicinale ayant un effet antitumoral |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH660964A5 true CH660964A5 (de) | 1987-06-30 |
Family
ID=21616776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH90284A CH660964A5 (de) | 1982-06-21 | 1982-06-21 | Arzneimittelpraeparat mit antikarzinogener wirkung. |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS59501110A (enExample) |
| CA (1) | CA1194802A (enExample) |
| CH (1) | CH660964A5 (enExample) |
| DE (1) | DE3249514T1 (enExample) |
| FR (1) | FR2535609A1 (enExample) |
| GB (1) | GB2134783B (enExample) |
| NL (1) | NL8220420A (enExample) |
| SE (1) | SE8400453L (enExample) |
| WO (1) | WO1984000105A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5344846A (en) * | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
| DE19628641C2 (de) * | 1996-07-16 | 1998-12-17 | Fresenius Ag | Verwendung von PHMB zur Behandlung von Tumorerkrankungen |
| RU2144024C1 (ru) * | 1998-10-28 | 2000-01-10 | Иркутский институт химии СО РАН | Способ получения фосфата полигексаметиленгуанидина |
| KR100557559B1 (ko) * | 1999-12-20 | 2006-03-03 | 에스케이 주식회사 | 폴리헥사메틸렌구아니딘 인산염 분말, 이의 제조방법 및이를 함유한 항균수지 |
| KR100725004B1 (ko) * | 1999-12-24 | 2007-06-04 | 에스케이 주식회사 | 살균소독제 조성물 및 이의 사용방법 |
| AT505312A1 (de) | 2007-05-15 | 2008-12-15 | Recticel Schlafkomfort Gmbh Sc | Polyurethan-werkstoff mit einer bioziden ausrüstung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3824288A (en) * | 1961-06-09 | 1974-07-16 | Hoffmann La Roche | Substituted hydrazine derivatives and process for the manufacture thereof |
| BR6457241D0 (pt) * | 1963-12-23 | 1973-06-26 | Rohm & Haas | Processo para a preparacao de t-octil-guanidinas |
| GB1492678A (en) * | 1975-08-11 | 1977-11-23 | Ici Ltd | Guanidine derivatives |
| JPS5341426A (en) * | 1976-09-27 | 1978-04-14 | Asahi Chem Ind Co Ltd | Fungicidal and bactericidal agents |
-
1982
- 1982-06-21 DE DE19823249514 patent/DE3249514T1/de not_active Withdrawn
- 1982-06-21 JP JP57503491A patent/JPS59501110A/ja active Pending
- 1982-06-21 CH CH90284A patent/CH660964A5/de not_active IP Right Cessation
- 1982-06-21 GB GB08403257A patent/GB2134783B/en not_active Expired
- 1982-06-21 NL NL8220420A patent/NL8220420A/nl not_active Application Discontinuation
- 1982-06-21 WO PCT/SU1982/000020 patent/WO1984000105A1/ru not_active Ceased
- 1982-10-07 CA CA000413032A patent/CA1194802A/en not_active Expired
- 1982-11-04 FR FR8218494A patent/FR2535609A1/fr active Granted
-
1984
- 1984-01-30 SE SE8400453A patent/SE8400453L/ not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE437931B (sv) | 1985-03-25 |
| CA1194802A (en) | 1985-10-08 |
| GB2134783B (en) | 1985-10-30 |
| JPS59501110A (ja) | 1984-06-28 |
| GB2134783A (en) | 1984-08-22 |
| DE3249514T1 (de) | 1984-05-17 |
| WO1984000105A1 (fr) | 1984-01-19 |
| SE8400453L (sv) | 1985-03-25 |
| SE8400453D0 (sv) | 1984-01-30 |
| GB8403257D0 (en) | 1984-03-14 |
| FR2535609A1 (fr) | 1984-05-11 |
| NL8220420A (nl) | 1984-05-01 |
| FR2535609B1 (enExample) | 1985-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2332878C2 (de) | Salze von Cephalosporinen mit Arginin und Lysin, ihre Herstellung und injizierbare pharmazeutische Zubereitungen | |
| EP0708640B1 (de) | Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält | |
| EP0276803B1 (de) | 1-(4-Hydroxy-3,5-di-tert.-butyl-benzoyl)-homopiperazin, verschiedene von dessen Derivaten, Verfahren zur Herstellung dieser Verbindungen, die sie enthaltenden Arzneimittel und ihre Verwendung | |
| DE2710327B2 (de) | Verwendung von Benzaldehyd | |
| DE3026180C2 (de) | Rifamycin-SV-Salze von basischen Aminosäuren, Verfahren zu ihrer Herstellung und Arzneimittel zur intraartikulären Injektion bei der Bekämpfung von rheumatoider Arthritis | |
| WO1985003507A2 (fr) | Sels de metallicenium et leur utilisation en tant qu'agents cytostatiques pour la lutte contre le cancer | |
| CH660964A5 (de) | Arzneimittelpraeparat mit antikarzinogener wirkung. | |
| DE2504331A1 (de) | Heptaminol-5'-adenosinmonophosphat und dessen therapeutische verwendung | |
| DE69429468T2 (de) | Antikrebs-Mitoxantrone-Polymer Zusammensetzung | |
| CH621334A5 (enExample) | ||
| EP0083439A2 (de) | 4-Sulfido-oxazaphosphorine und deren Verwendung bei der Krebsbekämpfung und zur Immunsuppression | |
| DE1768655B2 (enExample) | ||
| EP0037800B1 (de) | Verwendung von O-substituierten Derivaten von (+)-Cyanidanol-3 als Verbindungen mit immunomodulatorischen Eigenschaften | |
| DE1620177C3 (de) | N-(2-Hydroxyäthyl)-piperazinocarboxymethyl-tetracyclin, dessen pharmakologisch verwendbaren Salze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| EP0152860B1 (de) | Verwendung von Cephemverbindungen zur Herstellung eines Arzneimittels für die Modulation des Immunsystems | |
| DE2625220B2 (de) | Arzneimittel zur Behandlung von Leberkrankheiten | |
| DE3143592C2 (de) | Quaternäre N,N&uarr;3&uarr;-Di(ß-brompropionyl)-N',N&uarr;2&uarr;-dispirotripiperaziniumsalze, Verfahren zu deren Herstellung und Arzneimittel mit zytostatischer Wirkung | |
| DE2311905C3 (de) | 2-Dimethylamino-6-diäthylenimidophosphoramido-7-methylpurin, Verfahren zu dessen Herstellung und Arzneimittelpräparat auf der Basis dieser Verbindung | |
| DE69910810T2 (de) | Natriumsalz von 3-(4-cinnamyl-1-piperazinyl)-iminomethyl-rifamycin sv und verfahren zu seiner herstellung | |
| DE2347220C3 (de) | L-Cystin-bis-[2,2-bis-(2-chloräthyl)-hydrazid] -dihydrobromid, Verfahren zu seiner Herstellung und dieses enthaltende Arzneimittel | |
| EP0869817A2 (de) | Kovalente lipid-phosphonocarbonsäure-konjugate und ihre anwendung als antivirale arzneimittel | |
| DE2839224C2 (enExample) | ||
| DE3706431C2 (enExample) | ||
| DE2724608A1 (de) | Einen substituierten phenylaminoalkohol enthaltende pharmazeutische zubereitung, verfahren zu deren herstellung und deren verwendung | |
| DE1919895C (de) | 2 Phenyl 2 morpholinomethyl indan 1.3 dion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PLX | Patent declared invalid from date of grant onwards |